Annovis Bio (NYSE:ANVS) Upgraded to “Sell” at Wall Street Zen

Annovis Bio (NYSE:ANVS – Get Free Report) was upgraded by analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a note issued to investors on Saturday, Wall Street Zen reports.

A number of other research analysts also recently issued reports on ANVS. Canaccord Genuity Group restated a “buy” rating on shares of Annovis Bio in a research note on Tuesday, August 18th. Weiss Ratings cut shares of Annovis Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday. Finally, Roth Capital dropped their target price on shares of Annovis Bio from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Thursday, August 27th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $12.00.

Read Our Latest Research Report on ANVS

Annovis Bio Stock Performance

NYSE:ANVS opened at $0.93 on Friday. The firm has a market cap of $39.79 million, a price-to-earnings ratio of -0.52 and a beta of 1.36. Annovis Bio has a 52 week low of $0.62 and a 52 week high of $5.50. The firm has a 50-day moving average price of $1.10 and a two-hundred day moving average price of $1.82.

Annovis Bio (NYSE:ANVS – Get Free Report) last posted its earnings results on Friday, November 13th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.08. As a group, sell-side analysts forecast that Annovis Bio will post -1.32 earnings per share for the current year.

Insider Transactions at Annovis Bio

In related news, Director Michael Hoffman bought 5,000,000 shares of the business’s stock in a transaction on Friday, November 6th. The stock was acquired at an average price of $1.00 per share, for a total transaction of $5,000,000.00. Following the purchase, the director directly owned 8,364,883 shares in the company, valued at $8,364,883. This trade represents a 148.59% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 15.92% of the company’s stock.

Institutional Investors Weigh In On Annovis Bio

Several hedge funds and other institutional investors have recently modified their holdings of the stock. StoneX Group Inc. grew its position in Annovis Bio by 65.9% during the 3rd quarter. StoneX Group Inc. now owns 23,996 shares of the company’s stock worth $30,000 after acquiring an additional 9,531 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in Annovis Bio in the second quarter valued at approximately $29,000. Quadcap Wealth Management LLC bought a new stake in Annovis Bio in the second quarter valued at approximately $30,000. First National Trust Co lifted its position in Annovis Bio by 50.0% in the second quarter. First National Trust Co now owns 60,000 shares of the company’s stock valued at $112,000 after purchasing an additional 20,000 shares during the last quarter. Finally, Nicholson Wealth Management Group LLC purchased a new stake in shares of Annovis Bio during the third quarter valued at approximately $25,000. 15.83% of the stock is currently owned by institutional investors.

Annovis Bio Company Profile

(Get Free Report)

Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease. The company’s research centers on therapies designed to address mechanisms associated with neurodegeneration rather than treating only individual symptoms. Annovis Bio’s lead product candidate is buntanetap, formerly known as ANVS401. Buntanetap is an orally administered small molecule being investigated for its potential to reduce the production of multiple neurotoxic proteins linked to neurodegenerative disorders.

Further Reading

Receive News & Ratings for Annovis Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annovis Bio and related companies with MarketBeat.com's FREE daily email newsletter.